Hepatitis C is a liver disease caused by the hepatitis C virus (HCV) and infects approximately 75 million individuals worldwide. It is also one of the major causes of liver cancer and liver transplants. The elucidation of the HCV genome, and the development of a whole cell system to study the virus spurred the search for novel direct acting antiviral drugs to cure this disease. This global effort culminated in the development of direct acting antiviral drugs that led to cure rates approaching 100% in all patient populations after only 8-12 weeks of therapy. These efforts resulted in one of the greatest achievements in public health and provides the potential for eliminating HCV as a major disease worldwide.
This volume is aimed at a broad audience of academic and industrial scientists interested in the discovery and development of drugs to treat viral diseases and those interested in reading about one of the most unique accomplishments in biomedical research. The volume will provide a one of a kind reference work that highlights the many efforts, from the discovery of the HCV virus, to the invention of breakthrough medicines and their use in the real world to cure patients. It is the companion book to the volume "HCV: The Journey from Discovery to a Cure - Volume II".

lgli/N:\!genesis_\0day\new030220\springer\10.1007%2F978-3-030-28207-3.pdf

lgrsnf/N:\!genesis_\0day\new030220\springer\10.1007%2F978-3-030-28207-3.pdf

nexusstc/HCV: The Journey from Discovery to a Cure: Volume I/8910a27c0af5c5a0274feb6ef2e333a3.pdf

scihub/10.1007/978-3-030-28207-3.pdf

zlib/Medicine/Michael J. Sofia/HCV: The Journey from Discovery to a Cure: Volume I_5399765.pdf

HCV: The Journey from Discovery to a Cure; v.1

Sofia, Michael J.

Springer Nature Switzerland AG

Topics in Medicinal Chemistry, 31, 1st ed. 2019, Cham, 2019

Springer Nature, Cham, Switzerland, 2019

Switzerland, Switzerland

Dec 03, 2019

2, 20191123

sm78770172

producers:
Adobe PDF Library 10.0.1

{"container_title":"Topics in Medicinal Chemistry","edition":"1","isbns":["3030282066","3030282074","9783030282066","9783030282073"],"issns":["1862-2461","1862-247X"],"publisher":"Springer","series":"Topics in Medicinal Chemistry 31","source":"libgen_rs"}

类型: 图书

出版日期: 2019

出版社: Springer

页码: 463

Source title: HCV: The Journey from Discovery to a Cure: Volume I (Topics in Medicinal Chemistry (31))

Front Matter ....Pages i-viii
Front Matter ....Pages 1-1
From B to Non-B to C: The Hepatitis C Virus in Historical Perspective (Harvey J. Alter)....Pages 3-17
The Discovery of the Hepatitis C Virus (Michael Houghton)....Pages 19-27
HCV Molecular Virology and Animal Models (Mohsan Saeed, Eva Billerbeck, Charles M. Rice)....Pages 29-68
The Hepatitis C Virus Replicon System and Its Role in Drug Development (Ralf Bartenschlager, Volker Lohmann)....Pages 69-96
The Role of Interferon for the Treatment of Chronic Hepatitis C Virus Infection (Saleh A. Alqahtani, Mark S. Sulkowski)....Pages 97-113
Front Matter ....Pages 115-115
Evolution of HCV NS5B Nucleoside and Nucleotide Inhibitors (Aesop Cho)....Pages 117-139
The Discovery of Sofosbuvir: A Liver-Targeted Nucleotide Prodrug for the Treatment and Cure of HCV (Michael J. Sofia, Phillip A. Furman)....Pages 141-169
Evolution of HCV NS5B Non-nucleoside Inhibitors (William J. Watkins)....Pages 171-191
Discovery of Beclabuvir: A Potent Allosteric Inhibitor of the Hepatitis C Virus Polymerase (Robert G. Gentles)....Pages 193-228
Front Matter ....Pages 229-229
Evolution of HCV NS3/4a Protease Inhibitors (Nigel J. Liverton)....Pages 231-259
Development and Marketing of INCIVEK (Telaprevir; VX-950): A First-Generation HCV Protease Inhibitor, in Combination with PEGylated Interferon and Ribavirin (Ann D. Kwong, Robert B. Perni, Camilla S. Graham)....Pages 261-291
Discovery of Boceprevir, a Ketoamide-Derived HCV NS3 Protease Inhibitor, for Treatment of Genotype 1 Infections (Srikanth Venkatraman)....Pages 293-315
The Discovery and Early Clinical Evaluation of the HCV NS3/4A Protease Inhibitor Asunaprevir (BMS-650032) (Nicholas A. Meanwell, Ramkumar Rajamani, Paul M. Scola, Li-Qiang Sun)....Pages 317-354
The Invention of Grazoprevir: An HCV NS3/4a Protease Inhibitor (John A. McCauley, Michael T. Rudd)....Pages 355-387
The Discovery and Development of HCV NS3 Protease Inhibitor Paritaprevir (Keith F. McDaniel, Yi-Yin Ku, Ying Sun, Hui-Ju Chen, Jason Shanley, Timothy Middleton et al.)....Pages 389-413
Discovery and Development of the Next-Generation HCV NS3 Protease Inhibitor Glecaprevir (Guoqiang Wang, Jun Ma, Li-Juan Jiang, Yonghua Gai, Jiang Long, Bin Wang et al.)....Pages 415-440
Discovery of Voxilaprevir (GS-9857): The Pan-Genotypic Hepatitis C Virus NS3/4A Protease Inhibitor Utilized as a Component of Vosevi® (James G. Taylor)....Pages 441-457
Back Matter ....Pages 459-463

2019-11-26